Vaxcyte Reports Positive Phase 3 Data For VAX-31 Pneumococcal Vaccine

By Reuters News

Oct 5 (Reuters) - Vaxcyte, Inc. PCVX.O:

  • VAXCYTE REPORTS POSITIVE TOPLINE DATA FROM OPUS-1, THE PIVOTAL ADULT PHASE 3 TRIAL OF VAX-31, THE COMPANY’S 31-VALENT PNEUMOCOCCAL CONJUGATE VACCINE CANDIDATE

  • VAXCYTE - VAX-31 MEETS ALL PRESPECIFIED PRIMARY ENDPOINTS ACROSS AGE GROUPS COMPARED TO PCV20 AND/OR PCV21

  • VAXCYTE - VAX-31 WELL TOLERATED WITH SAFETY PROFILE SIMILAR TO PCV20 AND PCV21 ACROSS ALL AGES

  • VAXCYTE - VAX-31 MEETS NONINFERIORITY FOR ALL 32 SEROTYPE COMPARISONS IN ADULTS 18-49 VERSUS 50-64

  • VAXCYTE, INC.: TO REPORT RESULTS FROM OPUS-2 AND OPUS-3 ADULT PHASE 3 TRIALS IN FIRST HALF OF 2027

  • VAXCYTE - EXPECTS OPUS-2 AND OPUS-3 PHASE 3 TRIALS RESULTS IN H1 2027; BLA SUBMISSION PLANNED H1 2028

Further company coverage: PCVX.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.